Stock Scorecard



Stock Summary for Dare Bioscience Inc (DARE) - $2.91 as of 5/9/2025 9:51:40 PM EST

Total Score

7 out of 30

Safety Score

22 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for DARE

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for DARE

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for DARE

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for DARE

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for DARE (22 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 10
Trading Volume (Max of 10) 0
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for DARE

Cytek Biosciences, Inc. ( CTKB ) Reports Q1 Loss, Lags Revenue Estimates 5/8/2025 10:10:00 PM
Dare Bioscience, Inc. ( DARE ) Reports Q4 Loss, Misses Revenue Estimates 3/31/2025 9:15:00 PM
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025 - Dare Bioscience ( NASDAQ:DARE ) 3/24/2025 12:00:00 PM
Akoya Biosciences ( AKYA ) Reports Q4 Loss, Lags Revenue Estimates 3/17/2025 9:10:00 PM
Jazz Pharmaceuticals ( JAZZ ) Tops Q4 Earnings and Revenue Estimates 2/25/2025 10:45:00 PM
Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference - Dare Bioscience ( NASDAQ:DARE ) 1/9/2025 1:00:00 PM
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder ( FSAD ) - Dare Bioscience ( NASDAQ:DARE ) 12/16/2024 1:00:00 PM
Dare Bioscience, Inc. ( DARE ) Reports Q3 Loss, Lags Revenue Estimates 11/14/2024 10:10:00 PM
Immunome, Inc. ( IMNM ) Reports Q3 Loss, Misses Revenue Estimates 11/13/2024 10:15:00 PM
Absci Corporation ( ABSI ) Reports Q3 Loss, Misses Revenue Estimates 11/12/2024 1:50:00 PM

Financial Details for DARE

Company Overview

Ticker DARE
Company Name Dare Bioscience Inc
Country USA
Description Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's health products in the United States. The company is headquartered in San Diego, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 2.91
Price 4 Years Ago 24.00
Last Day Price Updated 5/9/2025 9:51:40 PM EST
Last Day Volume 5,546
Average Daily Volume 15,095
52-Week High 7.56
52-Week Low 2.67
Last Price to 52 Week Low 8.99%

Valuation Measures

Trailing PE N/A
Industry PE 30.10
Sector PE 47.92
5-Year Average PE -14.69
Free Cash Flow Ratio 1.64
Industry Free Cash Flow Ratio 18.49
Sector Free Cash Flow Ratio 30.82
Current Ratio Most Recent Quarter 0.85
Total Cash Per Share 1.77
Book Value Per Share Most Recent Quarter -0.69
Price to Book Ratio 10.75
Industry Price to Book Ratio 35.42
Sector Price to Book Ratio 27.83
Price to Sales Ratio Twelve Trailing Months 2,695.64
Industry Price to Sales Ratio Twelve Trailing Months 89.39
Sector Price to Sales Ratio Twelve Trailing Months 25.47
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 8,850,400
Market Capitalization 25,754,664
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 86.56%
Reported EPS 12 Trailing Months -0.48
Reported EPS Past Year 0.00
Reported EPS Prior Year -2.15
Net Income Twelve Trailing Months -4,053,599
Net Income Past Year -4,053,599
Net Income Prior Year -30,161,391
Quarterly Revenue Growth YOY -95.80%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 8,466.00%

Balance Sheet

Total Cash Most Recent Quarter 15,698,174
Total Cash Past Year 15,698,174
Total Cash Prior Year 10,476,056
Net Cash Position Most Recent Quarter 15,698,174
Net Cash Position Past Year 15,698,174
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 0.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year -6,012,089,000
Total Stockholder Equity Prior Year -5,047,640
Total Stockholder Equity Most Recent Quarter -6,012,089

Free Cash Flow

Free Cash Flow Twelve Trailing Months -15,190,840
Free Cash Flow Per Share Twelve Trailing Months -1.72
Free Cash Flow Past Year 4,821,201
Free Cash Flow Prior Year -39,486,084

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.01
MACD Signal 0.00
20-Day Bollinger Lower Band 2.74
20-Day Bollinger Middle Band 3.06
20-Day Bollinger Upper Band 3.38
Beta 1.20
RSI 48.11
50-Day SMA 7.45
150-Day SMA 0.00
200-Day SMA 10.25

System

Modified 5/9/2025 9:51:41 PM EST